Innate Pharma's new proprietary technology and its objectives Essay

Sanofi (NYSESNY) and Innate Pharma (OTCMKTSIPHYF) announced that they finalized a research deal accord as well as a licensing agreement for the acquisition of Innate Pharma's new proprietary technology.
By the virtue of this new technology, Sanofi will develop innovative bispecific antibody formats for natural killer cell or NK, cells for the destruction of tumor cells by activating receptor NKp46.
Both the drug companies will put their diligent efforts together for the development of at least two bispecific NK cell engagers.
Under the finalized deal, Sanofi will be responsible for development, manufacturing, and marketing aspects of products.
Innate Pharma will be eligible for a payment of 400 million ($436 million) by achieving the development and commercial milestone as well as royalties on net sales.
Innate Pharma shares sky rocketed to 15% after the announcement. Both the companies main target is to develop new concept and approach involving the immune system to kill cancer cells more efficiently with the aid of natural killer cells.
DEAL WITH WARP DRIVE BIO
Sanofi and Wrap Drive Bio, a biotechnology company, announced the extension and redesigning of their present collaboration. This deal will involve Warp Drive's proprietary SMARTTM (Small Molecule Assisted Receptor Targeting) and Genome Mining platforms for the discovery of oncology therapeutics and antibiotics.
Since establishment of Wrap Drive in 2012, Sanofi has been investing in the development of drugs and is a major strategic partner of Warp Drive Bio.
Both companies have entered into research collaboration in the development of drugs specifically emphasizing vital human oncogenes including RAS, having one of the highest mutation rates in cancer as well as development of new antibiotics targeting Gram-negative bacteria.
Under the terms and conditions of the agreement, Warp Drive Bio will have the right to retain its platforms to move forward in discovering and developing against all other targets either alone or with other companies in collaboration.
Furthermore as per the accord, Warp Drive will lead the collaboration for a time period of five years while Sanofi will be eligible for global specific rights for the development and commercialization of the drugs discovered in the said time period.
In the segments of research, regulatory milestones, clinical advancement, and development services, Warp Drive will be receiving cumulative payments in excess of $750 million.
In the beginning, both the companies will emphasize on three defined oncology programs specifically targeting multiple mutants and states of the RAS oncogenic protein.
All ex-US commercial activities will be managed by Sanofi while on the other hand Warp Drive will be entitled of commercial milestones and royalties on sales.
The companies also agreed on the discovery and development of Gram-negative therapeutics and Sanofi will lead all development activities.
In the Gram-negative segment, Sanofi has the global rights for the commercialization of products and will have to pay Warp Drive for research, clinical, and regulatory milestones along with tiered royalties and commercial milestones based on global sales.
Both the deals have enhanced the exposure of Sanofi in oncology research worth up to $1.2 billion.